How IV Ketamine May Affect Glutamate and Neuroplasticity in Menlo Park, CA

Ketamine is often discussed as though it works through a single, simple switch in the brain. It does not. The more honest answer is more interesting.

IV ketamine appears to affect glutamate, the brain’s most abundant excitatory chemical messenger. That initial change may set off downstream effects involving brain networks, synaptic connections, and the way the brain processes experience. Researchers are still clarifying the full picture. We believe you deserve that uncertainty stated plainly.

At Soft Reboot Wellness, we provide physician-supervised IV ketamine therapy for eligible patients in Menlo Park and San Francisco. Ketamine’s psychiatric uses are off-label, meaning the FDA has not approved IV ketamine specifically to treat psychiatric conditions. A consultation is where we consider your history, current care, medications, goals, and safety.

Glutamate Is Part of the Brain’s Everyday Conversation

Glutamate helps nerve cells communicate. It is involved in learning, memory, attention, movement, and emotional processing. It is not inherently good or bad. Like many signaling systems in the brain, it depends on timing, location, and balance.

Ketamine interacts with one type of glutamate receptor, called the NMDA receptor. In plain language, it temporarily changes how certain cells receive glutamate signals. This is not simply a matter of adding or subtracting a brain chemical. It may alter the rhythm of signaling across connected circuits.

Researchers have studied ketamine and other glutamate-receptor medications as possible approaches to depression, while also emphasizing that the evidence base has important limits, especially across different diagnostic groups and study designs. A systematic review of glutamate receptor modulators reflects both the scientific interest and the need for careful interpretation (Dean et al., 2021).

This is why we avoid reducing ketamine to a slogan about “fixing” glutamate. The brain is more complex than that. So is a person’s life.

From a Temporary Signal Change to Neuroplasticity

Neuroplasticity describes the brain’s capacity to change through experience. It can include strengthening, weakening, creating, or reorganizing connections between nerve cells. Neuroplasticity occurs throughout life. Sleep, stress, relationships, learning, illness, medication, and repeated habits can all be part of that larger process.

One proposed explanation for ketamine’s effects is that an initial shift in glutamate signaling may prompt downstream activity associated with synaptic plasticity. Synapses are the small points of communication between nerve cells. Scientists are investigating whether ketamine-related changes in these systems may help explain why some people report changes in mood or perspective after treatment.

That word, may, matters. Human brain research cannot yet show that every person receiving ketamine develops the same neural changes, or that a particular brain change will lead to a particular clinical result. Ketamine can also temporarily alter perception, thought, and sensory experience. Research using ketamine to model changes in brain-network connectivity illustrates how broadly its effects can extend beyond one receptor or one region (Abram et al., 2022).

The biological story is promising. It is not complete.

Why an Infusion Is Different From a Simple Dose

An IV infusion allows medication delivery to be carefully measured and observed in real time. That does not make the experience predictable. It does allow us to respond to the person in front of us.

During an infusion, some patients feel relaxed or detached. Others notice visual changes, altered time perception, emotional material, nausea, or discomfort. Some feel very little during the session. The subjective experience is not a scorecard for whether treatment is working.

We take time to explain what may happen before treatment begins. We also encourage practical preparation, including rest, transportation planning, and following pre-treatment instructions. Our guide to preparing for your infusion offers a useful starting point.

What the Evidence Can and Cannot Tell You

Clinical studies can describe patterns in groups. They cannot fully predict one individual’s course. That distinction is especially important when you are considering a treatment after a long period of distress.

For people with depression, ketamine has been studied in several settings, including treatment-resistant depression. Yet response, duration of benefit, side effects, and next steps vary. Interviews with people who received IV ketamine for treatment-resistant depression found that recovery narratives were often nuanced, with participants describing both meaningful shifts and ongoing difficulties. Those patient recovery narratives are a useful reminder that treatment is not a single event (Lapidos et al., 2023).

We also do not assume that a medication experience is separate from context. Your sleep, support system, ongoing therapy or psychiatric care, stress level, medical history, and expectations all matter. If you are comparing approaches, our discussion of ketamine and SSRIs may help frame questions for your prescribing clinician.

Why Physician-Led Care Matters

Ketamine is a controlled substance. It requires thoughtful prescribing, screening, monitoring, and follow-up. Potential risks may include temporary increases in blood pressure, dissociation, nausea, sedation, and psychological distress. A history of substance misuse, psychosis, certain medical conditions, or medication interactions may change whether treatment is appropriate.

Concerns about misuse and dependence deserve direct conversation, not alarmism or dismissal. A clinical discussion of ketamine prescribing notes the importance of careful patient selection, measured dosing, and ongoing monitoring when considering potential addiction risk. Guidance on judicious ketamine prescribing supports that cautious approach (Swainson et al., 2022).

Our role is to assess candidacy carefully and to provide a supervised setting. Learn more about physician-led ketamine care and the questions we consider before moving forward.

How We Think About the Space Around Treatment

We do not present ketamine as a replacement for every other form of care. Some patients continue working with a therapist, psychiatrist, primary care clinician, or other members of their care team. Some are exploring how ketamine-assisted psychotherapy differs from an infusion-based medical treatment. These are distinct conversations.

We emphasize informed consent, realistic expectations, and room for reflection. If treatment is appropriate, we want you to understand the possible benefits, limitations, alternatives, and risks before making a decision. We also want you to feel able to ask the question beneath the technical one: “Is this right for me, now?”

FAQ

Does ketamine permanently rewire the brain?

We cannot promise permanent brain changes. Neuroplasticity is an active area of research, but the precise relationship between ketamine, brain connectivity, and long-term outcomes remains uncertain. Your experience may differ from someone else’s.

Will I be awake during an IV ketamine infusion?

Patients are generally awake, though the experience may feel unusual or dreamlike. We monitor you throughout the infusion and discuss what to expect beforehand.

Do I need to stop my current medications?

Do not stop psychiatric or other prescribed medications on your own. We review your medications and coordinate with your existing clinicians when appropriate.

Is IV ketamine appropriate for everyone with anxiety, PTSD, or depression?

No. We offer ketamine for anxiety, PTSD, and depression only after an individualized medical evaluation. Safety, diagnosis, treatment history, current medications, and your broader care plan all matter.

Key Takeaways

IV ketamine may influence glutamate signaling and may activate downstream processes related to neuroplasticity. Those ideas are grounded in ongoing research, not certainty. The treatment experience and outcome can vary considerably.

If you are in immediate danger or having thoughts of harming yourself, call or text 988 for the 988 Suicide & Crisis Lifeline (988 Suicide and Crisis Lifeline, n.d.). For PTSD information and additional support, the National Center for PTSD offers education and resources (U.S. Department of Veterans Affairs, n.d.).

If you are considering IV ketamine in Menlo Park or San Francisco, we invite you to reach out at (650) 419-3330 to schedule a consultation. We can talk through your questions with care, clarity, and appropriate attention to the unknowns.

The content on this page is for educational purposes only and does not constitute medical advice. IV ketamine therapy is used off-label for psychiatric indications and is not FDA-approved for the treatment of depression. Individual results vary. Please discuss whether any treatment is appropriate for your specific health situation with a qualified medical provider.

Works Cited

1. Dean RL, et al. Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. https://pubmed.ncbi.nlm.nih.gov/34623633/

2. Abram SV, et al. Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia. https://pubmed.ncbi.nlm.nih.gov/35422467/

3. Lapidos A, et al. Patients’ recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression. https://pubmed.ncbi.nlm.nih.gov/36481228/

4. Swainson J, et al. Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing. https://pubmed.ncbi.nlm.nih.gov/35165841/

5. 988 Suicide and Crisis Lifeline. https://988lifeline.org/

6. U.S. Department of Veterans Affairs, National Center for PTSD. https://www.ptsd.va.gov/

Disclaimer

This article is for educational purposes only and is not a substitute for individualized evaluation, diagnosis, or treatment from a qualified healthcare professional.